quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:14:26·43d
SECFiling
Tenaya Therapeutics Inc. logo

Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

TNYA· Tenaya Therapeutics Inc.
Health Care
Original source

Companies

  • TNYA
    Tenaya Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jun 10UpdateWilliam Blair-
  • Nov 30UpdateLeerink Partners$7.00
  • Jun 15UpdateH.C. Wainwright$25.00
  • Aug 24UpdateCowen & Co.-
  • Aug 24UpdateMorgan Stanley$31.00
  • Aug 24UpdateChardan Capital$37.00

Related

  • SEC8d
    SEC Form DEFA14A filed by Tenaya Therapeutics Inc.
  • SEC8d
    SEC Form DEF 14A filed by Tenaya Therapeutics Inc.
  • SEC43d
    SEC Form 10-K filed by Tenaya Therapeutics Inc.
  • PR43d
    Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • PR46d
    Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
  • SEC50d
    Tenaya Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
  • PR50d
    Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
  • PR52d
    Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022